Extra: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
:The principle use of CD103 is to identify hairy cell leukaemia (HCL) and distinguish it from related diorders. CD103 also has a wider range of applications in the histopathological | :The principle use of CD103 is to identify hairy cell leukaemia (HCL) and distinguish it from related diorders. CD103 also has a wider range of applications in the histopathological identification of a range of myeloid and T-cell disorders. | ||
Revision as of 11:10, 12 June 2023
- Summary
- The principle use of CD103 is to identify hairy cell leukaemia (HCL) and distinguish it from related diorders. CD103 also has a wider range of applications in the histopathological identification of a range of myeloid and T-cell disorders.
Normal expression and function
CD103 belongs to the integrin family of adhesion proteins directing the adhesion of a subset of T cells to intestinal endothelium and other mucosal sites (binding to E-cadherin). In normal tissues CD103 is found mainly on normal intraepithelial T cells (both alpha-beta or gamma-delta type) and is also expressed by some peripheral regulatory T cells (TRegs) and specialised dendritic cells in the gut mucosa and mesenteric lymph nodes.
Diagnostic role
- CD103 is consistently expressed on hairy cell leukemia (HCL) with relatively high (although not complete) specificity.
- CD103 is not generally found on other B-cell lymphomas
Other useful information
In histopathology CD103 is used to identify enteropathy-associated T cell lymphoma, and in lung CD103 has been used in bronchoalveolar lavage to diagnose pulmonary sarcoidosis.
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
Expression in primitive cell types | |||||||
---|---|---|---|---|---|---|---|
AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
5-20%* | <5% | 80-100%** | 80-100% | <5% | <5% | 40-80% | 80-100% |
Notes: **While a good marker of B lineage it may not be expressed in more primitive phenotype ALL, there is also a recognised abberrant expression in AML (particularly cases with t)8;21)
Expression in mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
80-100%* | 80-100% | 80-100% | 80-100%** | 80-100%** | 40-80% | 80-100% | 5-20%*** |
Notes: Level of expression is important: *low expression in CLL; **typically high expression in HCL; ***generally absent in PCs
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
<5% | <5% | <5% | <5% | <5% |
summary tables
summary tables
1. expression by acute leukaemias and by haematogones
file rare pro-b all rare early pre-b all rare pre-b all rare early b all rare pro-t all rare mature-t all rare aml rare haemato-gones
- expression is reported to be associated with bcr-abl1 expression
2. expression by b-lymphoproliferative disorders file rare cll rare pll rare mcl rare fl hi hcl hi hclv rare mzl rare lpl rare pcs
link flow cytometry key considered a strong indicator to distinguish hcl and hclv from mzl